Drug intelligence / Profile preview

EDG-002

Development stage: Discontinued
Lead developer: Edgewise Therapeutics
Modality: Small Molecules
Administration: Parenteral

Overview

EDG-002 is an investigational **small molecule cardiac myosin modulator** developed by **Edgewise Therapeutics** for **inherited hypertrophic cardiomyopathy**. The program was described as targeting **cardiac myosin** through a novel mechanism intended to modulate cardiac muscle contractility in hypertrophic cardiomyopathy. Based on the provided context, EDG-002 remained in **preclinical development** and was later **discontinued** before advancing to clinical-stage development.

Targets

β-cardiac myosin S1 domain

Beyond the preview

Go deeper on EDG-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDG-002.

Explore the full profile